Multiple sclerosis (Houndmills, Basingstoke, England)最新文献

筛选
英文 中文
Prevalence, co-occurrence, and trajectories of pain, fatigue, depression, and anxiety in the year following multiple sclerosis diagnosis. 多发性硬化症诊断后一年疼痛、疲劳、抑郁和焦虑的患病率、共发率和轨迹
IF 5.8
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-04-01 Epub Date: 2021-06-16 DOI: 10.1177/13524585211023352
Thomas R Valentine, Kevin N Alschuler, Dawn M Ehde, Anna L Kratz
{"title":"Prevalence, co-occurrence, and trajectories of pain, fatigue, depression, and anxiety in the year following multiple sclerosis diagnosis.","authors":"Thomas R Valentine,&nbsp;Kevin N Alschuler,&nbsp;Dawn M Ehde,&nbsp;Anna L Kratz","doi":"10.1177/13524585211023352","DOIUrl":"https://doi.org/10.1177/13524585211023352","url":null,"abstract":"<p><strong>Background: </strong>Pain, fatigue, depression, and anxiety are common in multiple sclerosis, but little is known about the presence, co-occurrence, and trajectories of these symptoms in the year after multiple sclerosis (MS) diagnosis.</p><p><strong>Objectives: </strong>To determine, during the postdiagnosis year: (1) rates of pain, fatigue, depression, and anxiety; (2) rates of symptom co-occurrence; and (3) stability/change in symptom severity.</p><p><strong>Methods: </strong>Newly diagnosed adults with MS/clinically isolated syndrome (<i>N</i> = 230) completed self-report measures of pain, fatigue, depression, and anxiety at 1, 2, 3, 6, 9, and 12 months after MS diagnosis. Clinical significance was defined based on standardized cutoffs. Descriptive statistics and Sankey diagrams characterized rates and trajectories.</p><p><strong>Results: </strong>Participants endorsed clinically significant symptoms at some point in the postdiagnosis year at rates of 50.9% for pain, 62.6% for fatigue, 47.4% for depression, and 38.7% for anxiety. A majority of patients exhibited co-occurring symptoms-21.3% with two, 19.1% with three, and 17.4% with four. The proportions of patients with clinically significant symptoms were generally stable over time; however, rates of symptom development/recovery revealed fluctuations at the individual level.</p><p><strong>Conclusions: </strong>Pain, fatigue, depression, and anxiety are prevalent in newly diagnosed MS. Prompt screening and evidence-based interventions are necessary if quality of life is to be optimized.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"620-631"},"PeriodicalIF":5.8,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/13524585211023352","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39235353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis. 国家改善疾病治疗补贴政策对多发性硬化症患者长期残疾结局的影响
IF 5.8
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-04-01 Epub Date: 2021-08-13 DOI: 10.1177/13524585211035948
Suzi B Claflin, Julie A Campbell, Deborah F Mason, Tomas Kalincik, Steve Simpson-Yap, Richard Norman, Helmut Butzkueven, William M Carroll, Andrew J Palmer, C Leigh Blizzard, Ingrid van der Mei, Bruce V Taylor
{"title":"The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis.","authors":"Suzi B Claflin,&nbsp;Julie A Campbell,&nbsp;Deborah F Mason,&nbsp;Tomas Kalincik,&nbsp;Steve Simpson-Yap,&nbsp;Richard Norman,&nbsp;Helmut Butzkueven,&nbsp;William M Carroll,&nbsp;Andrew J Palmer,&nbsp;C Leigh Blizzard,&nbsp;Ingrid van der Mei,&nbsp;Bruce V Taylor","doi":"10.1177/13524585211035948","DOIUrl":"https://doi.org/10.1177/13524585211035948","url":null,"abstract":"<p><strong>Background: </strong>Disease-modifying therapies (DMTs) are used to treat people with relapsing-onset multiple sclerosis (ROMS), but our knowledge is largely limited to their short-term effects.</p><p><strong>Objective: </strong>To determine (1) the impact of national-level DMT subsidy policy on DMT use and health outcomes in people with MS (PwMS) and (2) the long-term effects of DMT on disability and quality of life (QoL; 5-level EQ-5D version (EQ-5D-5L) utility value).</p><p><strong>Methods: </strong>This observational cohort study compared Australian and New Zealand populations with different levels of DMT availability 10-20 years post-ROMS diagnosis. Between-country differences were assessed using standardised differences. Associations were assessed with multivariable linear regression models.</p><p><strong>Results: </strong>We recruited 328 Australians and 256 New Zealanders. The Australian cohort had longer DMT treatment duration, greater proportion of disease course treated and shorter duration between diagnosis and starting DMT. The Australian cohort had lower median Expanded Disability Status Scale (EDSS) (3.5 vs 4.0) and Multiple Sclerosis Severity Score (MSSS) (3.05 vs 3.71) and higher QoL (0.71 vs 0.65). In multivariable models, between-country differences in disability and QoL were largely attributed to differential use of DMT.</p><p><strong>Conclusions: </strong>This study provides evidence for the impact of national-level DMT policy on disability outcomes in PwMS. Where DMTs are more accessible, PwMS experienced less disability progression and improved QoL 10-20 years post-diagnosis.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"831-841"},"PeriodicalIF":5.8,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39307266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients. 新诊断多发性硬化症患者认知功能障碍的脑脊液炎症特征
IF 5.8
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-04-01 Epub Date: 2021-07-30 DOI: 10.1177/13524585211032510
Marco Pitteri, Roberta Magliozzi, Richard Nicholas, Stefano Ziccardi, Anna Isabella Pisani, Francesco Pezzini, Damiano Marastoni, Massimiliano Calabrese
{"title":"Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients.","authors":"Marco Pitteri,&nbsp;Roberta Magliozzi,&nbsp;Richard Nicholas,&nbsp;Stefano Ziccardi,&nbsp;Anna Isabella Pisani,&nbsp;Francesco Pezzini,&nbsp;Damiano Marastoni,&nbsp;Massimiliano Calabrese","doi":"10.1177/13524585211032510","DOIUrl":"https://doi.org/10.1177/13524585211032510","url":null,"abstract":"<p><strong>Background: </strong>The cerebrospinal fluid (CSF) molecular milieu is a marker of diffuse intrathecal inflammation in the meninges that, in turn, targets the grey matter (GM) in multiple sclerosis (MS). Cognitive impairment (CI) is associated with brain damage in MS and is often present early in people with MS (pwMS).</p><p><strong>Objective: </strong>To investigate whether a specific CSF inflammatory profile is associated with different degrees of CI in newly diagnosed pwMS.</p><p><strong>Methods: </strong>Sixty-nine pwMS and 43 healthy controls (HCs) underwent neuropsychological testing. The presence and levels of 57 inflammatory mediators in the CSF were assessed.</p><p><strong>Results: </strong>Apparently cognitively normal (ACN) pwMS had impaired executive functioning compared to HCs but performed better than pwMS with mild and severe CI (mCI and sCI) in all tests. CSF mediators involving innate immunity and immune activation and recruitment, differentiate ACN from pwMS with mCI, while CSF mediators related to B- and T-cell immunity and chemotaxis differentiate both ACN and mCI from those with sCI. CXCL13 was the only molecule that differentiated sCI from mCI pwMS.</p><p><strong>Conclusion: </strong>Specific CSF molecular patterns, reflecting the involvement of both innate and adaptive immune responses, are associated with the severity of CI in newly diagnosed pwMS.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"768-777"},"PeriodicalIF":5.8,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/13524585211032510","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39259998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Functional and structural MRI correlates of executive functions in multiple sclerosis. 多发性硬化症执行功能的功能和结构MRI相关性研究。
IF 5.8
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-04-01 Epub Date: 2021-08-13 DOI: 10.1177/13524585211033184
Olga Marchesi, Raffaello Bonacchi, Paola Valsasina, Paolo Preziosa, Elisabetta Pagani, Laura Cacciaguerra, Alessandro Meani, Lorenzo Conti, Damiano Mistri, Maria A Rocca, Massimo Filippi
{"title":"Functional and structural MRI correlates of executive functions in multiple sclerosis.","authors":"Olga Marchesi,&nbsp;Raffaello Bonacchi,&nbsp;Paola Valsasina,&nbsp;Paolo Preziosa,&nbsp;Elisabetta Pagani,&nbsp;Laura Cacciaguerra,&nbsp;Alessandro Meani,&nbsp;Lorenzo Conti,&nbsp;Damiano Mistri,&nbsp;Maria A Rocca,&nbsp;Massimo Filippi","doi":"10.1177/13524585211033184","DOIUrl":"https://doi.org/10.1177/13524585211033184","url":null,"abstract":"Background: Executive dysfunctions, including difficulties in attention, working memory, planning, and inhibition affect 15%–28% of multiple sclerosis (MS) patients. Objectives: To investigate structural and functional magnetic resonance imaging (MRI) abnormalities underlying executive function (EF) in MS patients. Methods: A total 116 MS patients and 65 controls underwent resting-state (RS) and diffusion-weighted sequences and neuropsychological examination, including Wisconsin Card Sorting Test (WCST) to test EF. Brain RS cognitive networks and fractional anisotropy (FA) from a priori selected white matter tracts were derived. Associations of WCST scores with RS functional connectivity (FC) and FA abnormalities were investigated. Results: In MS patients, predictors of working memory/updating were: lower corpus callosum (CC) FA, lower left working-memory network (WMN), right WMN RS FC for worse performance; lower executive control network (ECN), higher default-mode network (DMN), and salience network (SN) RS FC for better performance (R2 = 0.35). Predictors of attention were lower CC genu FA, lower left WMN, and DMN RS FC for worse performance; higher left WMN and ECN RS FC for better performance (R2 = 0.24). Predictors of worse shifting/inhibition were lower CC genu and superior cerebellar peduncle (SCP) FA, lower left WMN RS FC for worse performance; and higher ECN RS FC for better performance (R2 = 0.24). Conclusions: CC and SCP microstructural damage and RS FC abnormalities in cognitive networks underlie EF frailty in MS.","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"742-756"},"PeriodicalIF":5.8,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39307118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder. 多发性硬化症和视神经脊髓炎频谱障碍的海马结构和功能改变。
IF 5.8
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-04-01 Epub Date: 2021-08-11 DOI: 10.1177/13524585211032800
Fenglian Zheng, Yuxin Li, Zhizheng Zhuo, Yunyun Duan, Guanmei Cao, Decai Tian, Xinghu Zhang, Kuncheng Li, Fuqing Zhou, Muhua Huang, Haiqing Li, Yongmei Li, Chun Zeng, Ningnannan Zhang, Jie Sun, Chunshui Yu, Xuemei Han, Sven Hallar, Frederik Barkhof, Yaou Liu
{"title":"Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder.","authors":"Fenglian Zheng,&nbsp;Yuxin Li,&nbsp;Zhizheng Zhuo,&nbsp;Yunyun Duan,&nbsp;Guanmei Cao,&nbsp;Decai Tian,&nbsp;Xinghu Zhang,&nbsp;Kuncheng Li,&nbsp;Fuqing Zhou,&nbsp;Muhua Huang,&nbsp;Haiqing Li,&nbsp;Yongmei Li,&nbsp;Chun Zeng,&nbsp;Ningnannan Zhang,&nbsp;Jie Sun,&nbsp;Chunshui Yu,&nbsp;Xuemei Han,&nbsp;Sven Hallar,&nbsp;Frederik Barkhof,&nbsp;Yaou Liu","doi":"10.1177/13524585211032800","DOIUrl":"https://doi.org/10.1177/13524585211032800","url":null,"abstract":"<p><strong>Background: </strong>Hippocampal involvement may differ between multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD).</p><p><strong>Objective: </strong>To investigate the morphometric, diffusion and functional alterations in hippocampus in MS and NMOSD and the clinical significance.</p><p><strong>Methods: </strong>A total of 752 participants including 236 MS, 236 NMOSD and 280 healthy controls (HC) were included in this retrospective multi-center study. The hippocampus and subfield volumes, fractional anisotropy (FA) and mean diffusivity (MD), amplitude of low frequency fluctuation (ALFF) and degree centrality (DC) were analyzed, and their associations with clinical variables were investigated.</p><p><strong>Results: </strong>The hippocampus showed significantly lower volume, FA and greater MD in MS compared to NMOSD and HC (<i>p</i> < 0.05), while no abnormal ALFF or DC was identified in any group. Hippocampal subfields were affected in both diseases, though subiculum, presubiculum and fimbria showed significantly lower volume only in MS (<i>p</i> < 0.05). Significant correlations between diffusion alterations, several subfield volumes and clinical variables were observed in both diseases, especially in MS (<i>R</i> = -0.444 to 0.498, <i>p</i> < 0.05). FA and MD showed fair discriminative power between MS and HC, NMOSD and HC (AUC > 0.7).</p><p><strong>Conclusions: </strong>Hippocampal atrophy and diffusion abnormalities were identified in MS and NMOSD, partly explaining how clinical disability and cognitive impairment are differentially affected.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"707-717"},"PeriodicalIF":5.8,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39300542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Expansion of chronic MS lesions is associated with an increase of radial diffusivity in periplaque white matter. 慢性多发性硬化症病变的扩张与周围斑块白质的径向弥散性增加有关。
IF 5.8
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-04-01 Epub Date: 2021-08-11 DOI: 10.1177/13524585211033464
Samuel Klistorner, Michael H Barnett, Con Yiannikas, Joshua Barton, John Parratt, Yuyi You, Stuart L Graham, Alexander Klistorner
{"title":"Expansion of chronic MS lesions is associated with an increase of radial diffusivity in periplaque white matter.","authors":"Samuel Klistorner,&nbsp;Michael H Barnett,&nbsp;Con Yiannikas,&nbsp;Joshua Barton,&nbsp;John Parratt,&nbsp;Yuyi You,&nbsp;Stuart L Graham,&nbsp;Alexander Klistorner","doi":"10.1177/13524585211033464","DOIUrl":"https://doi.org/10.1177/13524585211033464","url":null,"abstract":"<p><strong>Background: </strong>Expansion of chronic multiple sclerosis (MS) lesion is associated with slow-burning inflammation at lesion rim. However, the underlying mechanisms leading to expansion are not fully understood.</p><p><strong>Objective: </strong>To investigate the relationship between diffusivity markers of demyelination and axonal loss in perilesional white matter and lesion expansion in relapsing-remitting MS (RRMS).</p><p><strong>Methods: </strong>T1, FLAIR and diffusion tensor images were acquired from 30 patients. Novel single-streamline technique was used to estimate diffusivity in lesions, perilesional white matter and normal-appearing white matter (NAWM).</p><p><strong>Results: </strong>Significant association was found between baseline periplaque radial diffusivity (RD) and subsequent lesion expansion. Conversely, periplaque axial diffusivity (AD) did not correlate with lesion growth. Baseline RD (but not AD) in periplaque white matter of expanding lesions was significantly higher compared with non-expanding lesions. Correlation between increase of both RD and AD in the periplaque area during follow-up period and lesion expansion was noticeably stronger for RD. Increase of RD in periplaque area was also much higher compared to AD. There was significant increase of AD and RD in the periplaque area of expanding, but not in non-expanding, lesions.</p><p><strong>Conclusion: </strong>Periplaque demyelination is likely to be an initial step in a process of lesion expansion and, as such, potentially represents a suitable target for remyelinating therapies.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"697-706"},"PeriodicalIF":5.8,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39300706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Ocrelizumab治疗复发缓解型多发性硬化症后对既往疾病改善治疗的次优反应:一项非随机对照试验
IF 5.8
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-04-01 Epub Date: 2021-08-12 DOI: 10.1177/13524585211035740
Bianca Weinstock-Guttman, Robert Bermel, Gary Cutter, Mark S Freedman, Thomas P Leist, Xiaoye Ma, Deidre Kile, Bruno Musch, Anthony T Reder, Jerry S Wolinsky
{"title":"Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.","authors":"Bianca Weinstock-Guttman,&nbsp;Robert Bermel,&nbsp;Gary Cutter,&nbsp;Mark S Freedman,&nbsp;Thomas P Leist,&nbsp;Xiaoye Ma,&nbsp;Deidre Kile,&nbsp;Bruno Musch,&nbsp;Anthony T Reder,&nbsp;Jerry S Wolinsky","doi":"10.1177/13524585211035740","DOIUrl":"https://doi.org/10.1177/13524585211035740","url":null,"abstract":"<p><strong>Background: </strong>Many patients with multiple sclerosis (MS) experience suboptimal disease control despite the use of disease-modifying therapy (DMT).</p><p><strong>Objective: </strong>To assess the efficacy and safety of ocrelizumab (OCR) in patients with relapsing-remitting MS (RRMS) and suboptimal response to prior DMTs.</p><p><strong>Methods: </strong>Patients with RRMS and suboptimal responses (one clinically reported relapse and/or lesion activity) after ⩾ 6 months on another DMT were enrolled. OCR 600 mg was given intravenously every 24 weeks. The primary outcome was no evidence of disease activity (NEDA), defined as the absence of protocol-defined relapse, confirmed disability progression (CDP), T1 Gd-enhancing lesions, and new/enlarging T2 lesions.</p><p><strong>Results: </strong>The intention-to-treat (ITT) population included 608 patients; NEDA was analyzed in a modified ITT (mITT) population (<i>n</i> = 576 (94.7%)). Over 96 weeks, 48.1% of mITT patients achieved NEDA, and most were free from protocol-defined relapse (89.6%), CDP (89.6%), and T1 Gd-enhancing lesions (95.5%); 59.5% had no new/enlarging T2 lesions. Safety observations were consistent with findings in the pivotal trials.</p><p><strong>Conclusion: </strong>Consistent efficacy of OCR on clinical and magnetic resonance imaging (MRI) disease activity measures and progression was shown in patients with RRMS and a suboptimal response to prior DMTs; no new safety signals were observed.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"790-800"},"PeriodicalIF":5.8,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2d/80/10.1177_13524585211035740.PMC8978461.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39303522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Reappraisal of CSF-specific oligoclonal bands in Asia. 亚洲csf特异性寡克隆带的再评价。
IF 5.8
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-04-01 Epub Date: 2021-10-06 DOI: 10.1177/13524585211048752
Ki Hoon Kim, Su-Hyun Kim, Na Young Park, Jae-Won Hyun, Ho Jin Kim
{"title":"Reappraisal of CSF-specific oligoclonal bands in Asia.","authors":"Ki Hoon Kim,&nbsp;Su-Hyun Kim,&nbsp;Na Young Park,&nbsp;Jae-Won Hyun,&nbsp;Ho Jin Kim","doi":"10.1177/13524585211048752","DOIUrl":"https://doi.org/10.1177/13524585211048752","url":null,"abstract":"<p><p>The prevalence of cerebrospinal fluid-specific oligoclonal bands (CSF-OCBs) was reported to be low in Asian people with multiple sclerosis (pwMS) compared to that in Western pwMS. It is yet to be determined whether it is a genuine feature of Asian pwMS or a misapprehension owing to past mis-classification of MS-mimicking diseases as MS. We aimed to reappraise the prevalence of CSF-OCBs in Korean pwMS after carefully excluding other central nervous system-inflammatory demyelinating diseases since 2017. Among 88 subjects, 78 (88.6%) were positive for CSF-OCBs, which suggests the prevalence of CSF-OCBs is not different between Korean and Western pwMS.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"665-668"},"PeriodicalIF":5.8,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39488307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder. 视神经脊髓炎谱系障碍患者血清生物标志物的纵向随访。
IF 5.8
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-04-01 Epub Date: 2021-07-02 DOI: 10.1177/13524585211024978
Hyunjin Kim, Eun-Jae Lee, Seungmi Kim, Lyn-Kyung Choi, Hyun-Ji Kim, Hye Weon Kim, Kyuyoon Chung, Dayoung Seo, Seongshin Moon, Kwang-Kuk Kim, Young-Min Lim
{"title":"Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder.","authors":"Hyunjin Kim,&nbsp;Eun-Jae Lee,&nbsp;Seungmi Kim,&nbsp;Lyn-Kyung Choi,&nbsp;Hyun-Ji Kim,&nbsp;Hye Weon Kim,&nbsp;Kyuyoon Chung,&nbsp;Dayoung Seo,&nbsp;Seongshin Moon,&nbsp;Kwang-Kuk Kim,&nbsp;Young-Min Lim","doi":"10.1177/13524585211024978","DOIUrl":"https://doi.org/10.1177/13524585211024978","url":null,"abstract":"<p><strong>Background: </strong>Recently, several serum biomarkers have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity.</p><p><strong>Objective: </strong>The objective of the study is to evaluate the longitudinal clinical value of serum biomarkers in patients with NMOSD.</p><p><strong>Methods: </strong>We prospectively recruited consecutive NMOSD patients with anti-aquaporin-4 antibody and obtained serum samples at enrollment, after 6-12 months of follow-up (main period), and at attacks. Using single-molecule array assays, we evaluated longitudinal changes of serum neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and GFAP/NfL levels.</p><p><strong>Results: </strong>Overall, 64 patients (58 women) were enrolled (age: 51 years, disease duration: 6.7 years) and 133 samples were obtained. Among patients who did not develop new attacks during the main period (<i>n</i> = 62), serum levels of NfL, GFAP, and GFAP/NfL were significantly decreased over time in patients with attacks (<2 months) at enrollment (<i>n</i> = 14 (23%)), whereas serum NfL and GFAP levels gradually increased in the others (<i>n</i> = 48 (77%)). During the study, five (8%) patients developed new attacks; only serum GFAP levels increased consistently upon these events compared with baseline levels. To differentiate attacks from remissions, serum GFAP levels showed the largest area under the receiver operating characteristic curve (0.876, 95% confidence interval: 0.801-0.951).</p><p><strong>Conclusion: </strong>Among NfL, GFAP, and GFAP/NfL, serum GFAP might be the most appropriate for monitoring NMOSD longitudinally, which warrants future confirming studies.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"512-521"},"PeriodicalIF":5.8,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/13524585211024978","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39156822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. 富马酸二甲酯治疗复发缓解型多发性硬化症长达13年的长期安全性和有效性:最终的背书研究结果
IF 5.8
Multiple sclerosis (Houndmills, Basingstoke, England) Pub Date : 2022-04-01 Epub Date: 2021-09-01 DOI: 10.1177/13524585211037909
Ralf Gold, Douglas L Arnold, Amit Bar-Or, Robert J Fox, Ludwig Kappos, Oksana Mokliatchouk, Xiaotong Jiang, Jennifer Lyons, Shivani Kapadia, Catherine Miller
{"title":"Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.","authors":"Ralf Gold,&nbsp;Douglas L Arnold,&nbsp;Amit Bar-Or,&nbsp;Robert J Fox,&nbsp;Ludwig Kappos,&nbsp;Oksana Mokliatchouk,&nbsp;Xiaotong Jiang,&nbsp;Jennifer Lyons,&nbsp;Shivani Kapadia,&nbsp;Catherine Miller","doi":"10.1177/13524585211037909","DOIUrl":"https://doi.org/10.1177/13524585211037909","url":null,"abstract":"<p><strong>Background: </strong>Dimethyl fumarate (DMF) demonstrated favorable benefit-risk in relapsing-remitting multiple sclerosis (RRMS) patients in phase-III DEFINE and CONFIRM trials, and ENDORSE extension.</p><p><strong>Objective: </strong>The main aim of this study is assessing DMF safety/efficacy up to 13 years in ENDORSE.</p><p><strong>Methods: </strong>Randomized patients received DMF 240 mg twice daily or placebo (PBO; Years 0-2), then DMF (Years 3-10; continuous DMF/DMF or PBO/DMF); maximum follow-up (combined studies), 13 years.</p><p><strong>Results: </strong>By January 2020, 1736 patients enrolled/dosed in ENDORSE (median follow-up 8.76 years (ENDORSE range: 0.04-10.98) in DEFINE/CONFIRM and ENDORSE); 52% treated in ENDORSE for ⩾6 years. Overall, 551 (32%) patients experienced serious adverse events (mostly multiple sclerosis (MS) relapse or fall; one progressive multifocal leukoencephalopathy); 243 (14%) discontinued treatment due to adverse events (4% gastrointestinal (GI) disorders). Rare opportunistic infections, malignancies, and serious herpes zoster occurred, irrespective of lymphocyte count. For DMF/DMF (<i>n</i> = 501), overall annualized relapse rate (ARR) remained low (0.143 (95% confidence interval (CI), 0.120-0.169)), while for PBO/DMF (<i>n</i> = 249), ARR decreased after initiating DMF and remained low throughout (ARR 0-2 years, 0.330 (95% CI, 0.266-0.408); overall ARR (ENDORSE, 0.151 (95% CI, 0.118-0.194)). Over 10 years, 72% DMF/DMF and 73% PBO/DMF had no 24-week confirmed disability worsening.</p><p><strong>Conclusion: </strong>Sustained DMF safety/efficacy was observed in patients followed up to 13 years, supporting DMF's positive benefit/risk profile for long-term RRMS treatment.</p>","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"801-816"},"PeriodicalIF":5.8,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/17/a8/10.1177_13524585211037909.PMC8978463.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39373766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 24
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信